Clinical trials: Diabetes, Type II
Obesity, Gliosis, Weight-Loss
A Cohort Study of Weight Loss and Gliosis
Patients and clinicians need better options to prevent the weight regain that almost universally follows a weight loss intervention. In lay terms, a new, higher "set point" seems to occur after people gain weight.
- Trial name
- NCT03578887
- Testing
- Behavioral Weight Loss Program, Roux-en-Y Gastric Bypass or Sleeve Gastrectomy
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Washington
Diabetes Mellitus, Type 2
Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM
The objective of the current study is to investigate the safety and tolerability of BI 1356 (5 mg / once daily) given for 78 weeks in different modalities of treatment.
- Trial name
- NCT00736099
- Testing
- linagliptine 5 mg, linagliptine 5 mg and pioglitazone 30 mg
- Where
- 232 sites in United States, Argentina and 30 more
- Volunteers
- 2,122 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)
A study to evaluate the efficacy and safety of sitagliptin and pioglitazone co-administration in comparison with sitagliptin and pioglitazone monotherapy in patients with type 2 diabetes.
- Trial name
- NCT00722371
- Testing
- Sitagliptin phosphate, Pioglitazone hydrochloride, Metformin
- Volunteers
- 1,615 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes
The primary research question is to evaluate whether, among patients with type 2 diabetes mellitus (T2D), initiation of empagliflozin changes the adjusted incidence of outcomes compared with initiation of Glucagon-Like Peptide-1…
- Trial name
- NCT03993132
- Testing
- Empagliflozin, Liraglutide
- Where
- Denmark
- Volunteers
- 26,774 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Anxiety about needles is a concern commonly expressed by diabetics when beginning insulin therapy. A shorter, thinner pen needle that delivers insulin with the safety and efficacy profile of longer pen needles may appeal to many…
- Trial name
- NCT01231984
- Testing
- 4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle
- Where
- 10 sites in United States
- Volunteers
- 293 people
- Sponsor
- Becton, Dickinson and Company
Diabetes, Periodontitis
Hyperbaric Oxygen Therapy as Adjunctive Therapy to Scaling and Root-planing in the Management of Periodontitis in Patients With Type 2 Diabetes
Diabetes and Periodontitis are both prevalent diseases affecting millions of Americans. Periodontitis is prevalent among Diabetics.
- Trial name
- NCT02671136
- Testing
- Hyperbaric Oxygen therapy, Conventional Wound Therapies
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Loma Linda University
Diabetes Mellitus, Type 2, Health Knowledge, Attitudes, Practice
Improving Diabetic Patient Health Through Assistive-Reading Technology
Type 2 Diabetes Mellitus (T2DM) affects over 30 million Americans and requires patients to competently manage their conditions at home.
- Conditions
- Diabetes Mellitus, Type 2, Health Knowledge, Attitudes, Practice, Literacy
- Trial name
- NCT05337306
- Testing
- GogyUp Reader
- Where
- United States
- Volunteers
- 193 people, healthy volunteers welcome
- Sponsor
- GogyUp Inc
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus
The purpose of this study is: To compare blood glucose (blood sugar) control on LY2605541 with insulin glargine after 26 weeks of treatment.
- Trial name
- IMAGINE 4 (NCT01468987)
- Testing
- LY2605541, Insulin Glargine, Insulin Lispro
- Where
- 156 sites in United States, Australia and 23 more
- Volunteers
- 1,369 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes
This is a stepped glucose clamp study designed to investigate the effect of treatment with albiglutide on counter-regulatory hormone responses and recovery from hypoglycemia in subjects with Type 2 diabetes mellitus.
- Trial name
- NCT01475734
- Testing
- albiglutide
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
Closed Loop Glucose Control in Patients With Type 2 Diabetes
This is a proof of concept safety study of an artificial intelligence based closed loop glucose control system designed for use in the intensive care unit setting.
- Trial name
- NCT05386849
- Testing
- FUSION closed loop glucose control system
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Ideal Medical Technologies
Type 2 Diabetes
Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes
The purpose of this study is to learn if BMS-477118 (Saxagliptin) as part of a triple combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes after 24 weeks of treatment compared to a 2 drug…
- Trial name
- NCT01619059
- Testing
- Saxagliptin, Dapagliflozin, Metformin IR
- Where
- 83 sites in United States, Canada and 7 more
- Volunteers
- 315 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)
To demonstrate bioequivalence of a 2.5 mg saxagliptin/1000 mg metformin (glucophage) immediate release (IR) fixed dose combination (FDC) tablet to the 2.5 mg saxagliptin tablet and 1000 mg metformin IR tablet co-administered to…
- Trial name
- NCT00897390
- Testing
- Saxagliptin, Metformin IR (glucophage), Saxagliptin + Metformin IR (FDC)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
The purpose of the study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to insulin glargine and metformin with or without thiazolidinediones (TZDs), over a period…
- Trial name
- GetGoal-Duo1 (NCT00975286)
- Testing
- Lixisenatide (AVE0010), Insulin glargine, Pen auto-injector
- Where
- 140 sites in United States, Argentina and 24 more
- Volunteers
- 446 people
- Sponsor
- Sanofi
Type 2 Diabetes
Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes
People who are overweight or who have type 2 diabetes mellitus (T2DM) have higher levels of certain fats in their blood. The blood vessels and heart of most of these individuals do not work normally and people with T2DM also have…
- Trial name
- AcT2 (NCT01580813)
- Testing
- Acipimox
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Colorado, Denver
Type 2 Diabetes
Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes
Background: Pioglitazone has been shown to have potent anti-inflammatory as well anti-atherosclerotic effects. However, the mechanisms by which pioglitazone exerts these effects are not clear.
- Trial name
- PIO-TACE (NCT01223196)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes Mellitus
Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)
This is a study of co-administration of ertugliflozin (MK-8835/PF-04971729) and sitagliptin given together or alone along with metformin in participants with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control on…
- Trial name
- NCT02099110
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 10 mg
- Volunteers
- 1,233 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Vinegar Co-ingestion in Type 2 Diabetes
The main objective of this study is to assess the acute effect of co-ingested vinegar on postprandial plasma glucose levels in type 2 diabetes patients.
- Trial name
- NCT01279317
- Testing
- vinegar co-ingestion
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Maastricht University Medical Center
Obesity, Diabetes Mellitus, Type 2
Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes
Single center, single-dose, randomized, placebo-controlled, dose-escalating study to evaluate, safety, tolerability, pharmacokinetics, and pharmacodynamics of escalating doses of ENT-03S in obese but otherwise healthy subjects…
- Trial name
- NCT05925920
- Testing
- ENT-03
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Metabolics Pharma
Diabetes Mellitus, Type 2
Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises
Obesity is common in African American (AA) patients with newly diagnosed diabetes who present with diabetic ketoacidosis (DKA). Despite the presentation with severe symptoms of insulinopenia and ketoacidosis, clinical and…
- Trial name
- NCT00753142
- Testing
- Intralipid 20%, Glucose infusion
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Emory University
Diabetes Mellitus in Pregnancy
SweetMama: Testing of a Novel Technology for Diabetes Education and Support to Pregnant Women
Diabetes during pregnancy is a challenging clinical situation requiring substantial patient engagement. The investigators have developed a novel early-phase tool, called SweetMama, that incorporates educational, motivational and…
- Trial name
- NCT03240874
- Testing
- SweetMama Focus Groups, SweetMama Individual Testing, SweetMama Feasibility Testing - Pilot Randomized Trial
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Northwestern University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.